Acceleron Pharma, Inc. (XLRN)
Stock Price:
$97.67 USD
-1.45 (-1.46%)
Updated Aug 10, 2020 11:52 AM EDT - Market open
Key Info
| Market Cap |
5.80B |
| Revenue (ttm) |
87.64M |
| Net Income (ttm) |
-138.33M |
| Shares Out |
59.90M |
| EPS (ttm) |
-2.60 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$97.67 |
| Previous Close |
$99.12 |
| Change ($) |
-1.45 |
| Change (%) |
-1.46% |
| Day's Open |
99.02 |
| Day's Range |
96.95 - 100.55 |
| Day's Volume |
146,344 |
| 52-Week Range |
37.60 - 110.75 |
More Stats
| Market Cap |
5.80B |
| Enterprise Value |
5.44B |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
59.90M |
| Float |
52.53M |
| EPS (basic) |
-2.59 |
| EPS (diluted) |
-2.60 |
| FCF / Share |
-2.73 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.35M |
| Short Ratio |
2.78 |
| Short % of Float |
7.01% |
| Beta |
0.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
66.22 |
| PB Ratio |
15.30 |
| Revenue |
87.64M |
| Operating Income |
-144.99M |
| Net Income |
-138.33M |
| Free Cash Flow |
-147.13M |
| Net Cash |
366.40M |
| Net Cash / Share |
6.17 |
| Gross Margin |
-91.23% |
| Operating Margin |
-165.43% |
| Profit Margin |
-157.80% |
| FCF Margin |
-167.88% |
| ROA |
-17.59% |
| ROE |
-30.02% |
| ROIC |
-57.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (12)
| Buy |
10 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$126.67*
(29.69% upside)
Low
89.0
Current: $97.67
High
137.0
Target: 126.67
*Average 12-month price target from 12 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 73.99 | 13.99 | 13.48 | 27.77 | 18.10 | 14.63 | 57.23 | 15.25 | 80.91 |
| Revenue Growth | 428.86% | 3.78% | -51.46% | 53.46% | 23.68% | -74.43% | 275.18% | -81.15% | - |
| Gross Profit | 73.99 | 13.99 | 13.48 | 27.77 | 18.10 | 14.63 | 57.23 | 15.25 | 79.41 |
| Operating Income | -136 | -124 | -110 | -66.11 | -60.88 | -55.46 | 6.95 | -28.89 | 38.56 |
| Net Income | -125 | -119 | -108 | -57.01 | -63.89 | -51.26 | -21.90 | -32.58 | 70.42 |
| Shares Outstanding | 52.45 | 45.90 | 40.42 | 37.43 | 33.30 | 31.52 | 9.41 | 2.40 | 2.33 |
| Earnings Per Share | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -4.15 | -24.84 | 0.78 |
| Operating Cash Flow | -93.80 | -94.71 | -76.54 | -44.55 | -44.21 | -53.22 | -19.65 | -38.88 | 9.06 |
| Capital Expenditures | -3.29 | -2.59 | -4.40 | -3.38 | -0.96 | -0.51 | -0.31 | -0.44 | -0.03 |
| Free Cash Flow | -97.09 | -97.30 | -80.94 | -47.93 | -45.17 | -53.73 | -19.96 | -39.33 | 9.03 |
| Cash & Equivalents | 431 | 291 | 278 | 141 | 106 | 177 | 114 | 40.52 | 65.95 |
| Total Debt | 26.38 | - | - | - | - | - | 16.87 | 20.19 | 6.00 |
| Net Cash / Debt | 405 | 291 | 278 | 141 | 106 | 177 | 97.21 | 20.33 | 59.95 |
| Assets | 505 | 315 | 389 | 248 | 146 | 186 | 124 | 49.21 | 73.79 |
| Liabilities | 55.43 | 22.78 | 23.96 | 22.05 | 37.07 | 30.01 | 65.92 | 71.58 | 64.93 |
| Book Value | 449 | 292 | 365 | 226 | 109 | 156 | 57.81 | -291 | -233 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Acceleron Pharma, Inc. |
| Country |
United States |
| Employees |
237 |
| CEO |
Habib J. Dable |
Stock Information
| Ticker Symbol |
XLRN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: XLRN |
| IPO Date |
September 19, 2013 |
Description
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.